Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Financial Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting - Audited Financial Results, Dividend Declaration, Director Appointment

Audit Opinion:

Standalone Financial Results: Modified opinion with emphasis of matter regarding going concern

Consolidated Financial Results: Unmodified opinion

Auditor's Comment: The standalone auditor's report highlights material uncertainty about the company's ability to continue as a going concern due to accumulated losses and negative retained earnings.

Key Financial Highlights [₹ in Lakh]:

Standalone Results:

Revenue from Operations (FY26): ₹41,349 lakh vs ₹30,985 lakh (YoY increase)

Total Income (FY26): ₹43,149 lakh

Net Profit/(Loss) after tax (FY26): (₹2,988) lakh vs (₹1,523) lakh (YoY deterioration)

EPS (FY26): (₹4.88) vs (₹2.49) (YoY deterioration)

Other Equity (FY26): ₹27,911 lakh vs ₹30,784 lakh (YoY decrease)

Cash and Cash Equivalents (FY26): ₹241 lakh vs ₹3,850 lakh (YoY decrease)

Debt (Non-current + Current borrowings) (FY26): ₹26,512 lakh (₹24,594 + ₹1,918) vs ₹22,845 lakh (₹16,051 + ₹6,794) (YoY increase)

Consolidated Results:

Revenue from Operations (FY26): ₹63,977 lakh vs ₹55,909 lakh (YoY increase)

Total Income (FY26): ₹65,667 lakh

Net Profit/(Loss) after tax (FY26): (₹716) lakh vs (₹872) lakh (YoY improvement)

EPS (FY26): (₹0.88) vs (₹1.37) (YoY improvement)

Other Equity (FY26): ₹82,871 lakh vs ₹82,866 lakh (YoY stable)

Cash and Cash Equivalents (FY26): ₹5,731 lakh vs ₹8,213 lakh (YoY decrease)

Segment-wise Performance [₹ in Lakh]:

Consolidated Segment Revenue (FY26):

  • Vaccines: ₹41,025 lakh vs ₹30,984 lakh (YoY increase)
  • Formulations: ₹22,952 lakh vs ₹24,925 lakh (YoY decrease)
  • Total: ₹63,977 lakh vs ₹55,909 lakh (YoY increase)

Consolidated Segment Results (Profit/Loss before tax) (FY26):

  • Vaccines: (₹2,684) lakh vs (₹1,652) lakh (YoY deterioration)
  • Formulations: ₹1,947 lakh vs ₹857 lakh (YoY improvement)
  • Total: (₹737) lakh vs (₹795) lakh (YoY improvement)

Corporate Actions:

Dividend: No dividend declared on equity or preference shares for financial year 2025-26 due to losses

Other Significant Information:

Going Concern: Company reported standalone loss of ₹2,874 lakh for FY26 with negative retained earnings of ₹21,782 lakh as of March 31, 2026, indicating material uncertainty about going concern

Exceptional Items: Consolidated exceptional income of ₹1,950 lakh includes ₹857 lakh from settlement with Apotex Inc. and ₹1,092 lakh from deferred consideration of brand sale

DengiAll Vaccine: Phase-III clinical trial enrollment completed, expected market entry by 2027 after regulatory approvals

Labour Codes: Impact of new labour codes accounted for based on available information

Deferred Tax: Standalone and consolidated results include deferred tax adjustments of (₹153) lakh and ₹36 lakh respectively for earlier years

Entities in Consolidation:

The consolidated financial results include:

  • Panacea Biotec Pharma Limited (Audited Indian WOS)
  • Meyten Realtech Private Limited (Audited Indian WOS)
  • Panacea Biotec Inc. (Overseas WOS through PBPL)
  • Panacea Biotec (International) S.A. (Unaudited Overseas WOS)
  • Panacea Biotec Germany GmbH (WOS through PBS)
  • PanEra Biotec Private Limited (Enterprise under control)
  • Adveta Power Private Limited (Enterprise under control)